Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dingli

Showing results (291-300 of 471) with videos related to

Pageof 48
Sort By:
Blood Advances|April 12, 2022
Outcomes after biochemical or clinical progression in patients with multiple myelomaSarah Goldman-Mazur, Alissa Visram, Prashant Kapoor, et al.
Leukemia|April 9, 2024
Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failuresSaurabh Zanwar, Morie A Gertz, Eli Muchtar, et al.
Leukemia & Lymphoma|July 15, 2021
Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysisAbdullah S Al Saleh, Alissa Visram, Harsh Parmar, et al.
Transplantation and Cellular Therapy|April 11, 2021
Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) AmyloidosisEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
Blood Cancer Journal|July 23, 2024
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myelomaMatthew J Rees, Aytaj Mammadzadeh, Abiola Bolarinwa, et al.
European Journal of Haematology|December 1, 2020
Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomideYi L Hwa, Martha Q Lacy, Morie A Gertz, et al.
Bone Marrow Transplantation|August 9, 2018
Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete responseM Hasib Sidiqi, Mohammed A Aljama, Dragan Jevremovic, et al.
Mayo Clinic Proceedings|May 10, 2017
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic ExperienceTaxiarchis V Kourelis, Robert A Kyle, David Dingli, et al.
American Journal of Hematology|December 17, 2019
Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivityMarcella Tschautscher, Dragan Jevremovic, Francis K Buadi, et al.
American Journal of Hematology|June 25, 2016
Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluationYi L Hwa, Shaji K Kumar, Morie A Gertz, et al.
Pageof 48

Showing results (291-300 of 471) with videos related to

Sort By:
Pageof 48
Blood Advances|April 12, 2022
Outcomes after biochemical or clinical progression in patients with multiple myelomaSarah Goldman-Mazur, Alissa Visram, Prashant Kapoor, et al.
Leukemia|April 9, 2024
Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failuresSaurabh Zanwar, Morie A Gertz, Eli Muchtar, et al.
Leukemia & Lymphoma|July 15, 2021
Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysisAbdullah S Al Saleh, Alissa Visram, Harsh Parmar, et al.
Transplantation and Cellular Therapy|April 11, 2021
Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) AmyloidosisEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
Blood Cancer Journal|July 23, 2024
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myelomaMatthew J Rees, Aytaj Mammadzadeh, Abiola Bolarinwa, et al.
European Journal of Haematology|December 1, 2020
Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomideYi L Hwa, Martha Q Lacy, Morie A Gertz, et al.
Bone Marrow Transplantation|August 9, 2018
Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete responseM Hasib Sidiqi, Mohammed A Aljama, Dragan Jevremovic, et al.
Mayo Clinic Proceedings|May 10, 2017
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic ExperienceTaxiarchis V Kourelis, Robert A Kyle, David Dingli, et al.
American Journal of Hematology|December 17, 2019
Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivityMarcella Tschautscher, Dragan Jevremovic, Francis K Buadi, et al.
American Journal of Hematology|June 25, 2016
Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluationYi L Hwa, Shaji K Kumar, Morie A Gertz, et al.
Pageof 48